摘要
BackgroundCamrelizumab has shown encouraging efficacy in advanced non-small cell lung cancer (NSCLC), either as monotherapy or combined with chemotherapy. However, evidence of neoadjuvant camrelizumab for NSCLC remains lacking.MethodsPatients with NSCLC treated with neoadjuvant camrelizumab-based therapy followed by surgery between December 2020 and September 2021 were retrospectively reviewed. Demographic and clinical data, details of neoadjuvant therapy and surgical information were retrieved.ResultsIn this multicenter retrospective real-world study, 96 patients were included. Ninety-five patients (99.0%) received neoadjuvant camrelizumab combined with platinum-based chemotherapy, with a median of 2 cycles (range 1-6). The median interval from the last dose to surgery was 33 days (range 13-102 days). Seventy patients (72.9%) underwent minimally invasive surgery. Lobectomy was the most frequent surgical procedure (94 [97.9%]). The median estimated intraoperative blood loss was 100 mL (range 5-1200 mL), and the median operative time was 3.0 h (range 1.5-6.5 h). The R0 resection rate was 93.8%. Twenty-one patients (21.9%) experienced postoperative complications, with the most common being cough and pain (both 6 [6.3%]). The overall response rate was 77.1% (95% CI 67.4-85.0%), and the disease control rate was 93.8% (95% CI 86.9-97.7%). Twenty-six patients (27.1%, 95% CI 18.5-37.1%) had pathological complete response. Neoadjuvant treatment-related adverse events of grade >= 3 were reported in seven patients (7.3%), with the most frequent being abnormal liver enzymes (two [2.1%]). No treatment-related deaths were reported.ConclusionThe real-world data indicated that camrelizumab-based therapy had promising efficacy for NSCLC in the neoadjuvant setting, with manageable toxicities. Prospective studies investigating neoadjuvant camrelizumab are warranted.
学科与关键词
- Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real- world retrospective observational study (CTONG2004-ADV)Xu, Chong-Rui; Chen, Qixun; Zhou, Chengzhi; Wu, Lin; Li, Wen; Zhang, Huizhong; Li, Yongsheng; Xu, Fei; Xiong, Jianping; Wang, Qiming; Zhang, Haibo; Jiang, Yuequan; Yin, Haitao; Wu, Qingchen; Dai, Qiangsheng; Hu, Jian; Chen, Jianhua; Zhang, Jian; Wu, Gang; Yin, Jun; Zhao, Jianfu; Liu, Baogang; Shan, Jianzhen; Sheng, Liming; Chen, Qunqing; Han, Zhengxiang; Shi, Huaqiu; Liu, Yimin; Chen, Jun; Wu, Yi-Long*Translational Lung Cancer Research, 2023, 12(1): 127-+.
- Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): A retrospective real-world study (CTONG2004)Xu, C.; Chen, Q.; Zhou, C.; Wu, L.; Li, W.; Zhang, H.; Li, Y.; Xu, F.; Xiong, J.; Wang, Q.; Zhang, H.; Jiang, Y.; Yin, H.; Wu, Q.; Dai, Q.; Hu, J.; Chen, J.; Zhang, J.; Wu, G.; Wu, Y-L.ESMO Immuno-Oncology Congres, ELECTR NETWORK, 2021-12-08 To 2021-12-11.被引 2
- Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II studyLiu, Si-Yang; Dong, Song; Yang, Xue-Ning; Liao, Ri-Qiang; Jiang, Ben-Yuan; Wang, Qun; Ben, Xiao-Song; Qiao, Gui-Bin; Lin, Jun-Tao; Yan, Hong-Hong; Yan, Li-Xu; Nie, Qiang; Tu, Hai-Yan; Wang, Bin-Chao; Yang, Jin-Ji; Zhou, Qing; Li, Hong-Rui; Liu, Ke; Wu, Wendy; Liu, Si-Yang Maggie; Zhong, Wen-Zhao*; Wu, Yi-Long*Signal Transduction and Targeted Therapy, 2023, 8(1): 442.
